Venolife (Gel) Instructions for Use

Marketing Authorization Holder

Akrikhin Chemical and Pharmaceutical Plant, JSC (Russia)

Contact Information

AKRIKHIN JSC (Russia)

ATC Code

C05BA53 (Heparin in combination with other drugs)

Active Substances

Dexpanthenol (Rec.INN registered by WHO)

Heparin sodium (Rec.INN registered by WHO)

Troxerutin (Rec.INN registered by WHO)

Dosage Form

Venolife

Gel for external use 0.25 g+5 g+2 g/100 g: tubes 40 g or 100 g

Dosage Form, Packaging, and Composition

Gel for external use transparent or almost transparent, light yellow in color, with a specific odor.

Excipients: phenylethanol, propylene glycol, carbomer 940 or 980, trometamol, purified water.

40 g – aluminum tubes (1) – cardboard packs.
100 g – aluminum tubes (1) – cardboard packs.

Clinical-Pharmacological Group

A drug with antithrombotic, angioprotective, venotonic, and tissue regeneration-improving action for topical use

Pharmacotherapeutic Group

Direct-acting anticoagulant for topical use + other drugs

Pharmacological Action

A combined drug for external use, the pharmacological properties of which are determined by the action of its constituent substances.

Heparin is a direct-acting anticoagulant, a natural anticoagulant factor of the body. It has an anti-inflammatory effect, promotes the regeneration of connective tissue by inhibiting the activity of hyaluronidase; prevents thrombus formation, activates the fibrinolytic properties of blood, and improves local blood flow.

Dexpanthenol is a provitamin B₅ that is converted in the skin into pantothenic acid, which is part of coenzyme A, which plays an important role in acetylation and oxidation processes. By improving metabolic processes, dexpanthenol promotes the regeneration of damaged tissues; improves the absorption of heparin.

Troxerutin is an angioprotective agent. It has P-vitamin activity, in particular, it reduces vascular-tissue permeability and capillary fragility, promotes the normalization of microcirculation and tissue trophism, reduces congestion in the veins and paravenous tissues, and has an anti-exudative and anti-inflammatory effect.

Pharmacokinetics

With topical application, the active substances are quickly absorbed through the skin. Heparin accumulates in the upper layers and actively binds to skin proteins, dexpanthenol penetrates all layers of the skin and is converted into pantothenic acid, troxerutin is detected in the dermis after 30 minutes, and after 2-5 hours – in the subcutaneous adipose tissue.

Indications

• Edema-pain syndrome and microcirculatory-trophic disorders caused by venous insufficiency of the lower extremities (varicose veins, acute and chronic thrombophlebitis, post-thrombophlebitic syndrome, chronic lymphostasis);
• Soft tissue injuries (hematomas, dislocations, sprains);
• To accelerate granulation and epithelialization of trophic ulcers in the regeneration phase (in the absence of pronounced exudation).

ICD codes

Dosage Regimen

Externally. Apply a thin layer to the affected area 2-3 times/day, evenly distributing over the skin surface with light rubbing movements until completely absorbed. The course of treatment is 2-3 weeks.

For trophic ulcers with weak exudation, before using the drug, the wound surface should be cleaned of exudate and necrotic tissues, if necessary, rinsed with a 3% hydrogen peroxide solution, 1:5000 nitrofural solution, or 0.05% chlorhexidine digluconate solution and dried. The gel is applied in a uniform thin layer so that the entire affected surface is covered with the drug, and a sterile gauze bandage is applied. Dressings are changed once a day. With the open method of treatment, the drug is applied 1-2 times/day. The duration of treatment is determined by the dynamics of epithelialization.

Adverse Reactions

Possible local manifestations of allergic reactions (skin rash, itching).

Contraindications

• Open infected wounds or wounds with abundant exudation at the site of application;
• Children under 1 year of age;
• Hypersensitivity to the components of the drug.

Use in Pregnancy and Lactation

Venolife can be used during pregnancy and lactation (breastfeeding).

Pediatric Use

Contraindicated for use in children under 1 year of age.

Special Precautions

Venolife is not intended for use in ophthalmology, for intravaginal and rectal administration.

Overdose

Overdose is unlikely due to the low systemic absorption of the gel components.

Drug Interactions

No interactions of Venolife with other medicinal products have been identified.

Storage Conditions

The drug should be stored out of the reach of children at a temperature from 15°C (59°F) to 25°C (77°F).

Shelf Life

Shelf life – 2 years. Do not use after the expiration date.

Dispensing Status

The drug is available without a prescription.

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.